- Home
- GENK vs GANX Comparison
GENK vs GANX Comparison
Compare GENK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- GANX
- Stock Information
- Founded
- GENK 2011
- GANX 2017
- Country
- GENK United States
- GANX United States
- Employees
- GENK N/A
- GANX N/A
- Industry
- GENK Restaurants
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- GANX Health Care
- Exchange
- GENK Nasdaq
- GANX Nasdaq
- Market Cap
- GENK 41.1M
- GANX 41.9M
- IPO Year
- GENK 2023
- GANX 2021
- Fundamental
- Price
- GENK $7.53
- GANX $1.56
- Analyst Decision
- GENK Strong Buy
- GANX Strong Buy
- Analyst Count
- GENK 3
- GANX 5
- Target Price
- GENK $13.17
- GANX $7.60
- AVG Volume (30 Days)
- GENK 60.0K
- GANX 214.8K
- Earning Date
- GENK 11-12-2024
- GANX 11-14-2024
- Dividend Yield
- GENK N/A
- GANX N/A
- EPS Growth
- GENK 483.78
- GANX N/A
- EPS
- GENK 0.17
- GANX N/A
- Revenue
- GENK $198,834,000.00
- GANX N/A
- Revenue This Year
- GENK $14.66
- GANX N/A
- Revenue Next Year
- GENK $21.47
- GANX N/A
- P/E Ratio
- GENK $43.70
- GANX N/A
- Revenue Growth
- GENK 12.50
- GANX N/A
- 52 Week Low
- GENK $5.61
- GANX $0.89
- 52 Week High
- GENK $14.46
- GANX $5.33
- Technical
- Relative Strength Index (RSI)
- GENK 39.46
- GANX 40.79
- Support Level
- GENK $7.10
- GANX $1.50
- Resistance Level
- GENK $8.45
- GANX $1.73
- Average True Range (ATR)
- GENK 0.51
- GANX 0.16
- MACD
- GENK -0.08
- GANX -0.00
- Stochastic Oscillator
- GENK 22.22
- GANX 16.22
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.